| Literature DB >> 28878204 |
Liming Tan1, Anjun Jiao2, Juanjuan Chen1, Xiaojing Feng2, Liuyue Xu2, Siqi He2, Fuyan Tan2, Yongqing Jiang1, Heng Luo1, Hua Li1, Yang Wu1, Yongjian Tian1, Tingting Zeng1, Jianlin Yu1, Liping Cao1, Jianfeng Zheng1, Hui Xu1, Ming Wei1, Wen Gan1, Weihua Peng3, Yanming Liu4, Jing Hou5, Jiangxia Xu6, LiHua Shuai7, Wenzhi Huang8, Junyun Huang8, Yan Lin9, Jianrong Liu10.
Abstract
BACKGROUND The discovery of antineutrophil cytoplasm antibody (ANCA) makes the early diagnosis of primary vasculitis possible, and also has important guiding significance for the diagnosis and treatment of secondary vasculitis. This study aimed to investigate the clinical significance of ANCA. MATERIAL AND METHODS ANCA was detected by indirect immunofluorescence assay (IIF), and anti-myeloperoxidase (MPO) antibody, and anti-proteinase 3 (PR3) antibody were detected by ELISA. The results were analyzed retrospectively. RESULTS Among 118 730 patients, a total of 5853 (4.93%) were positive for ANCA. In the positive cases, 3.98% were male and 6.33% were female, with significant differences (χ²=123.38, P<0.01). For ANCA, the department with the highest positive rate (15.06%) was the Department of Rheumatology, followed by 7.78% in the Department of Dermatology, 6.79% in the Department of Nephrology, and 5.72% in the Department of Traditional Chinese Medicine (TCM). Anti-PR3 and cANCA were highly specific in primary vasculitis (P<0.01). Anti-MPO and pANCA had high specificity for other autoimmune diseases (P<0.01). CONCLUSIONS ANCA has important guiding significance for vasculitis-related diseases. Therefore, it is important in the diagnosis and treatment of this disease and has value in clinical practice.Entities:
Mesh:
Substances:
Year: 2017 PMID: 28878204 PMCID: PMC5600193 DOI: 10.12659/msm.905880
Source DB: PubMed Journal: Med Sci Monit ISSN: 1234-1010
ANCA test results.
| Number of cases | Number of positive cases | Positive rate (%) | |
|---|---|---|---|
| Male | 41633 | 1657 | 3.98 |
| Female | 77097 | 4196 | 6.33 |
| χ2 | 123.38 | ||
| P | <0.01 |
The χ2 test was used, and the results showed that ANCA-positivity was associated with sex (χ2=123.38, P<0.01).
Departmental distribution with cases positive for ANCA.
| Department | Number checked | Positive number | Positive rate (%) | Department | Number checked | Positive number | Positive rate (%) |
|---|---|---|---|---|---|---|---|
| Rheumatology | 28894 | 4352 | 15.06 | Department of Infectious Diseases | 3720 | 134 | 3.60 |
| Nephrology | 20350 | 1382 | 6.79 | Pediatrics | 808 | 34 | 4.21 |
| Neurology | 11210 | 255 | 1.79 | Traditional Chinese Medicine | 4723 | 270 | 5.72 |
| Gastroenterology | 12100 | 471 | 3.89 | Dermatology | 1207 | 94 | 7.78 |
| Hematology | 10732 | 328 | 3.06 | Geriatrics | 721 | 35 | 4.85 |
| Respiratory medicine | 11906 | 576 | 4.84 | General surgery | 140 | 20 | 1.43 |
| Painful disease | 980 | 24 | 2.45 | Outpatient | 10239 | 655 | 6.39 |
The results of anti-PR3, anti-MPO, and ANCA antibody in 5853 cases.
| Group | Number of cases | Anti-PR3-positive | Anti-MPO-positive | ANCA-positive | |||||
|---|---|---|---|---|---|---|---|---|---|
| cANCA-positive | pANCA-positive | ||||||||
| Number of cases | % | Number of cases | % | Number of cases | % | Number of cases | % | ||
| Vasculitis | 2053 | 748 | 41.31 | 708 | 29.61 | 667 | 32.49 | 760 | 37.02 |
| Other autoimmune diseases | 3612 | 457 | 12.65 | 2140 | 59.25 | 329 | 9.11 | 2779 | 79.94 |
| Other | 188 | 45 | 23.94 | 105 | 55.85 | 50 | 26.60 | 106 | 56.38 |
| Healthy physical examination group | 100 | 0 | 0.00 | 0 | 0.00 | 0 | 0.00 | 0 | 0.00 |
| Total | 5953 | 1295 | 21.75 | 3062 | 51.44 | 1096 | 18.41 | 3751 | 63.01 |
Compared with vasculitis and autoimmune diseases, by χ2 test, P<0.01, the results had a very significant significance.
Compared with vasculitis, by χ2 test, P<0.01, the results had a very significant significance.
MPO antibody and anti-PR3concentration test results.
| Group | Number of cases | Anti-PR3-positive | Anti-MPO-positive | ||
|---|---|---|---|---|---|
| Number of cases | Concentration (IU/ml) | Number of cases | Concentration (IU/ml) | ||
| Vasculitis | 2053 | 748 | 31.65±17.75 | 708 | 47.23±21.58 |
| Other autoimmune diseases | 3612 | 457 | 18.22±10.91 | 2140 | 74.58±41.10 |
| Other diseases | 188 | 45 | 6.28±3.39 | 105 | 7.48± 7.86 |
Compared with other autoimmune diseases, the results were very significant (P<0.01) in the rank sum test.
The 5853 cases with ANCA-confirmed clinical diagnosis and positive rate.
| Disease type | Detection of total number of cases | Number of positive cases | Positive rate (%) |
|---|---|---|---|
| WG | 972 | 696 | 71.60 |
| MPA | 983 | 659 | 67.03 |
| CSS | 317 | 173 | 54.57 |
| PAN | 572 | 251 | 43.88 |
| TA | 298 | 121 | 40.60 |
| IgAV | 251 | 99 | 39.44 |
| BD | 220 | 54 | 24.55 |
| AIH | 7655 | 54 | 0.71 |
| PBC | 6008 | 115 | 1.91 |
| PSC | 7434 | 98 | 1.32 |
| RA | 21773 | 825 | 3.79 |
| SLE | 19297 | 1182 | 6.13 |
| UC | 10450 | 565 | 5.41 |
| MCTD | 10358 | 404 | 3.90 |
| PSS | 7026 | 82 | 1.17 |
| SS | 7572 | 287 | 3.79 |
| T2DM | 12541 | 75 | 0.60 |
| 5003 | 113 | 2.25 | |
Positive rate of anti-MPO, anti-PR3 antibody, and 2 patterns of ANCA in different diseases.
| Disease types | Number of cases | Anti-PR3-positive | Anti-MPO-positive | ANCA-positive | |||||
|---|---|---|---|---|---|---|---|---|---|
| cANCA-positive | pANCA-positive | ||||||||
| Number of cases | % | Number of cases | % | Number of cases | % | Number of cases | % | ||
| WG | 696 | 523 | 75.14 | 24 | 3.45 | 473 | 67.96 | 13 | 1.88 |
| MPA | 659 | 101 | 15.33 | 358 | 54.32 | 84 | 12.75 | 379 | 57.51 |
| CSS | 173 | 18 | 10.40 | 90 | 52.02 | 15 | 8.76 | 95 | 54.91 |
| PAN | 251 | 22 | 8.76 | 125 | 49.80 | 22 | 8.76 | 142 | 56.57 |
| TA | 121 | 59 | 48.76 | 35 | 28.92 | 44 | 36.36 | 49 | 40.49 |
| IgAV | 99 | 23 | 23.23 | 42 | 44.44 | 25 | 25.25 | 46 | 46.46 |
| BD | 54 | 2 | 3.70 | 22 | 40.74 | 4 | 7.41 | 26 | 48.15 |
| AIH | 54 | 3 | 5.56 | 27 | 50.00 | 5 | 9.26 | 33 | 6.11 |
| PBC | 115 | 12 | 10.43 | 55 | 47.83 | 9 | 7.83 | 78 | 67.83 |
| PSC | 98 | 1 | 1.02 | 52 | 53.06 | 0 | 0 | 56 | 57.14 |
| RA | 825 | 223 | 27.03 | 251 | 30.42 | 119 | 14.42 | 704 | 85.33 |
| SLE | 1182 | 20 | 1.69 | 1018 | 86.13 | 27 | 2.28 | 1037 | 87.73 |
| UC | 565 | 29 | 5.13 | 361 | 63.89 | 22 | 3.89 | 454 | 80.35 |
| MCTD | 404 | 110 | 27.23 | 141 | 34.90 | 112 | 27.72 | 169 | 41.83 |
| PSS | 82 | 5 | 6.10 | 10 | 12.20 | 2 | 2.43 | 17 | 20.73 |
| SS | 287 | 54 | 18.82 | 225 | 78.40 | 33 | 11.50 | 231 | 80.49 |
| T2DM | 75 | 17 | 22.67 | 35 | 46.67 | 19 | 25.33 | 40 | 53.33 |
| 113 | 28 | 24.78 | 70 | 61.95 | 31 | 27.43 | 66 | 58.41 | |
Organ involvement related with pANCA and cANCA.
| Type of involvement | Total number of cases | cANCA-positive (1046) | pANCA-positive (3645) | χ2 | ||
|---|---|---|---|---|---|---|
| Number of cases | Positive rate (%) | Number of cases | Positive rate (%) | |||
| Kidney involvement | 1484 | 283 | 27.06 | 1201 | 32.95 | 0.67 |
| Liver involvement | 1397 | 209 | 19.98 | 1188 | 32.59 | 159.36 |
| Eye involvement | 342 | 121 | 11.57 | 221 | 6.06 | 36.43 |
| Ear involvement | 354 | 65 | 6.21 | 299 | 8.20 | 4.14 |
| Nasal involvement | 279 | 33 | 3.15 | 215 | 5.90 | 8.12 |
| Joint involvement | 544 | 129 | 12.33 | 415 | 11.39 | 5.78 |
| Muscle involvement | 438 | 71 | 6.79 | 367 | 10.07 | 10.34 |
| Nervous system involvement | 268 | 44 | 4.21 | 224 | 6.15 | 5.57 |
| Digestive tract involvement | 741 | 101 | 9.66 | 640 | 17.56 | 38.16 |
| Other organs involved | 69 | 24 | 2.29 | 45 | 1.23 | 6.30 |
Compared with pANCA, the results were significant by χ2 test (P<0.05).
Compared with pANCA, the results are very significant by χ2 test (P<0.01).
Clinical evaluation of anti-PR3, anti-MPO antibody, and ANCA results.
| Test items | Sensitivity (%) | Specificity (%) | Prevalence (%) | Positive predictive value (%) | Negative predictive value (%) | Positive likelihood ratio (%) | Negative likelihood ratio (%) |
|---|---|---|---|---|---|---|---|
| Anti-PR3 | 62.02 | 70.74 | 21.27 | 36.43 | 87.35 | 2.12 | 53.69 |
| Anti-MPO | 24.86 | 52.25 | 50.27 | 34.49 | 40.75 | 0.52 | 143.81 |
| cANCA | 66.97 | 70.31 | 17.58 | 32.49 | 90.89 | 2.26 | 46.98 |
| pANCA | 21.47 | 39.18 | 62.27 | 37.02 | 23.06 | 0.35 | 200.43 |